308 related articles for article (PubMed ID: 35935969)
1. Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract][Full Text] [Related]
2. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
3. CRISPR screen in regulatory T cells reveals modulators of Foxp3.
Cortez JT; Montauti E; Shifrut E; Gatchalian J; Zhang Y; Shaked O; Xu Y; Roth TL; Simeonov DR; Zhang Y; Chen S; Li Z; Woo JM; Ho J; Vogel IA; Prator GY; Zhang B; Lee Y; Sun Z; Ifergan I; Van Gool F; Hargreaves DC; Bluestone JA; Marson A; Fang D
Nature; 2020 Jun; 582(7812):416-420. PubMed ID: 32499641
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells.
Kim D; Hong A; Park HI; Shin WH; Yoo L; Jeon SJ; Chung KC
J Cell Physiol; 2017 Dec; 232(12):3664-3676. PubMed ID: 28160502
[TBL] [Abstract][Full Text] [Related]
6. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.
Huang X; Zhang Q; Lou Y; Wang J; Zhao X; Wang L; Zhang X; Li S; Zhao Y; Chen Q; Liang T; Bai X
Cancer Immunol Res; 2019 Oct; 7(10):1580-1590. PubMed ID: 31399419
[TBL] [Abstract][Full Text] [Related]
7. Dissenting degradation: Deubiquitinases in cell cycle and cancer.
Bonacci T; Emanuele MJ
Semin Cancer Biol; 2020 Dec; 67(Pt 2):145-158. PubMed ID: 32201366
[TBL] [Abstract][Full Text] [Related]
8. Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth.
Xu H; Liu YL; Yang YM; Dong XS
Int J Colorectal Dis; 2012 Jan; 27(1):21-30. PubMed ID: 21773699
[TBL] [Abstract][Full Text] [Related]
9. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.
Gennaro VJ; Stanek TJ; Peck AR; Sun Y; Wang F; Qie S; Knudsen KE; Rui H; Butt T; Diehl JA; McMahon SB
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9298-E9307. PubMed ID: 30224477
[TBL] [Abstract][Full Text] [Related]
10. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.
Ning Z; Wang A; Liang J; Xie Y; Liu J; Feng L; Yan Q; Wang Z
Int J Oncol; 2014 Oct; 45(4):1594-608. PubMed ID: 24993031
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression.
Sun T; Zhang K; Li W; Liu Y; Pangeni RP; Li A; Arvanitis L; Raz DJ
Cell Commun Signal; 2022 Sep; 20(1):147. PubMed ID: 36123698
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.
Qiu GZ; Mao XY; Ma Y; Gao XC; Wang Z; Jin MZ; Sun W; Zou YX; Lin J; Fu HL; Jin WL
Cancer Sci; 2018 Jul; 109(7):2199-2210. PubMed ID: 29788550
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 22 (USP22) positively regulates RCAN1 protein levels through RCAN1 de-ubiquitination.
Hong A; Lee JE; Chung KC
J Cell Physiol; 2015 Jul; 230(7):1651-60. PubMed ID: 25546086
[TBL] [Abstract][Full Text] [Related]
14. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A.
Zhang XY; Pfeiffer HK; Thorne AW; McMahon SB
Cell Cycle; 2008 Jun; 7(11):1522-4. PubMed ID: 18469533
[TBL] [Abstract][Full Text] [Related]
15. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1.
Atanassov BS; Dent SY
EMBO Rep; 2011 Sep; 12(9):924-30. PubMed ID: 21779003
[TBL] [Abstract][Full Text] [Related]
16. USP22 controls iNKT immunity through MED1 suppression of histone H2A monoubiquitination.
Zhang Y; Wang Y; Gao B; Sun Y; Cao L; Genardi SM; Wang CR; Li H; Sun Z; Yang Y; Fang D
J Exp Med; 2020 May; 217(5):. PubMed ID: 32069354
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
Kim SB; Hwang S; Cha JY; Lee HJ
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling.
Xu G; Cai J; Wang L; Jiang L; Huang J; Hu R; Ding F
Exp Cell Res; 2018 Jan; 362(2):268-278. PubMed ID: 29174979
[TBL] [Abstract][Full Text] [Related]
19. USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination.
Roedig J; Kowald L; Juretschke T; Karlowitz R; Ahangarian Abhari B; Roedig H; Fulda S; Beli P; van Wijk SJ
EMBO Rep; 2021 Feb; 22(2):e50163. PubMed ID: 33369872
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling.
Liu H; Liu N; Zhao Y; Zhu X; Wang C; Liu Q; Gao C; Zhao X; Li J
Aging (Albany NY); 2019 Nov; 11(21):9643-9660. PubMed ID: 31689236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
